JCEM: The effect of abapatide vs alendronate on the reduction of fracture risk in postmenopausal women with osteoporosis.

Background: ACTIVE studies have demonstrated Abba Pa anti-fracture efficacy of osteoporosis in postmenopausal peptide

Abba Pa peptide of postmenopausal osteoporosis in patients with anti-fracture efficacy of alendronate sodium may reduce the AC TIVE patients receiving continuous treatment of fracture risk Aba Pa peptide

OBJECTIVE: To compare the anti-fracture curative effect of abatapatide and alendronate in AC TIVExtend

Design: In this retrospective analysis, the rate of new vertebral fractures (N = 1139) was calculated based on baseline and endpoint X-rays.

Results: The rate of vertebral fractures treated with abaparatide (0.

Figure Comparison of the incidence of new vertebral fracture events in subjects treated with alendronate and abaparatide; the placebo/alendronate group (grey bar) and the abaparatide group (green bar) in ACTIVExtend ) Reduction of new vertebral fractures,

Figure Comparison of the incidence of new vertebral fracture events in subjects treated with alendronate and abaparatide; the placebo/alendronate group (grey bar) and the abaparatide group (green bar) in ACTIVExtend ) Reduction of new vertebral fractures,

And each group of participants who received alendronate treatment (purple bar); ABL, aparatide; ALN, alendronate; M ITT, modified intention to treat; PBO, placebo

And each group of participants who received alendronate treatment (purple bar); ABL, aparatide; ALN, alendronate; M ITT, modified intention to treat; PBO, placebo

Table alendronate and abaparatide treatment subjects fracture incidence comparison; comparison based on age category adjusted Poisson regression model (<65, 65-<75, ≥75 years old)

Table alendronate and abaparatide treatment subjects fracture incidence comparison; comparison based on age category adjusted Poisson regression model (<65, 65-<75, ≥75 years old)

PT-years, patient-years; ¹ The effective drug course of study abaratide is 18 months

Compared with alendronic acid, abaparatide has a better effect on the reduction of vertebral fractures in postmenopausal patients with osteoporosis

Leder BZ, Mitlak B, Hu MY, et al, Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.

Leave a message here